| Literature DB >> 33472427 |
Hans Christoph Diener1, Messoud Ashina2, Isabelle Durand-Zaleski3,4, Tobias Kurth5, Michel Lantéri-Minet6, Richard B Lipton7, Daniel A Ollendorf8, Patricia Pozo-Rosich9,10, Cristina Tassorelli11,12, Gisela Terwindt13.
Abstract
The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments.Entities:
Keywords: Health technology assessment (HTA); International Headache Society (IHS); acute therapy; migraine; position statement; preventive treatment
Mesh:
Year: 2021 PMID: 33472427 PMCID: PMC7961634 DOI: 10.1177/0333102421989247
Source DB: PubMed Journal: Cephalalgia ISSN: 0333-1024 Impact factor: 6.292